KR101962266B1 - Anti-inflammatory Composition Using an Essential Oil Extract of Vitex rotundifolia - Google Patents

Abstract

The present invention discloses an essential oil extract of Vitex rotundifolia leaves or fruits, which inhibits the production of NO and inflammatory cytokines in a LPS-stimulated murine macrophage cell line, and has an antimicrobial activity against: propionibacterium acnes CCARM 9009 which is propionibacterium acnes; staphylococcus epidermidis CCARM 3709 which is Staphylococcus epidermidis; and staphylococcus aureus CCARM 0027 which is staphylococcus aureus.

Description

TECHNICAL FIELD The present invention relates to a composition for anti-inflammatory or antimicrobial use,

The present invention relates to a composition for anti-inflammation or a composition for antibacterial use using an essential oil extract of Vitex rotundifolia .

The inflammatory response is a mechanism to repair and regenerate damaged tissue as a defense against external physical and chemical stimuli and various infectious agents including tissue damage (Zamora R et al., Mol. Med. 6: 347-373 (2000) ; Mariathasan S and Monack DM. Nat. Rev. Immunol. 7: 31-40 (2007); Lee HN et al., J. Food Sci. Technol. 43: 65-71 (2011)). During the inflammation reaction, plasma accumulates on the inflamed area, diluting the toxicities secreted by the bacteria, increasing the blood flow, and accompanied by symptoms such as erythema, pain, edema, and fever. In normal cases, the organism neutralizes or eliminates the onset factor through inflammatory reaction, regenerates the upper tissue and regenerates the normal structure and function, but chronic inflammatory reaction, which is continuously or excessively caused, causes tissue damage. This inflammatory response induces progression to stomach, colon, bladder, and prostate cancer, and causes various diseases such as rheumatoid arthritis and chronic infection (Hofseth LJ and Ying L. Biochim. Biophys. Acta 1765: 74-84 (2006 ; Yun HY et al., Rev. Neurobiol. 10: 291-316 (1996); Stuehr DJ et al., P. Natl. Acad Sci. USA 88: 7773-7777 (1991)).

(IL-1β), IL-6, IL-6, IL-6, IL-6, IL-6, IL-6, and IL-6 in the presence of inflammatory mediators such as macrophages and monocytes. 8, and IL-12 (Guha M and Mackman N. Cell Signal. 13: 85-94 (2001)). A typical example of an inflammatory response is activation of the toll like receptor (TLR) signaling pathway of macrophages by pathogen associated molecular patterns (PAMPs). Lipopolysaccharide (LPS), a type of endotoxin present in the outer membrane of gram-negative bacteria, belongs to the inflammatory mediator PAMPs present in external microorganisms. TLR4 recognizes LPS with the help of MD-2 or CD14 (Miyake K. Trends Microbiol. 12: 186-192 (2004)), and the lower signaling pathway (NF-κB), which is a transcription factor, which activates NF-κB (NF-κB). Food Sci. Technol. 41: 477-482 (2009)). NF-κB translocated to the nucleus was found to be an inflammatory cytokine (TNF-α, IL-1β, IL-6, IL-8 and IL-12), inducible nitric oxide synthase (iNOS), cyclooxygenase-2 Nitric oxide (NO) induced by iNOS induces gene expression and exacerbates inflammation (Noh KH et al., J. Korean Soc. Food Sci. Nutr. 40: 625-634 (2011) ; Weisze et al., Biochem. J. 316: 209-215 (1996)). Nitric oxide, which is produced by iNOS in macrophages, reacts with superoxide to form peroxynitrite, which acts as a strong oxidizing agent and damages the cells, resulting in a variety of pathologies including inflammation and cancer (Gupta SC et al., Exp Biol Med., 236: 658-671, (2011); Riehemann et al., FEBS Lett., 442: 89-94 (1999)).

Although synthetic medicines such as ibuprofen, antihistamines, steroids, cortisone, immunosuppressants, and immunosuppressants are used, the therapeutic effect is temporary, there are many side effects such as simple symptom relief, hypersensitivity reaction and aggravation of the immune system Fundamental treatment of inflammation is difficult. Non-steroidal anti-inflammatory drugs (NSAIDS), which are now widely used as anti-inflammatory drugs, are known to cause serious side effects such as gastrointestinal disturbances, liver disorders, and renal insufficiency (Rainsford KD, Subcell biochem. , 42: 3-27, 2007, Guruprasad P. Aithal., Rheumatology., 7: 139-150, 2011, Praveen PN Rao et al., Pharmaceuticals., 3: 1530-1549, 2010).

On the other hand, human skin is an organ in direct contact with the surrounding environment, and infections such as bacteria and fungi which are involved in various skin diseases are easily caused. For example, Stein Staphylococcus aureus causing maturation skin Philo nose Syracuse aureus (Staphylococcus aureus) for Philo, including skin flora Stein nose Syracuse epidermidis (Staphyococcus epidermidis), acne bacteria is Propionibacterium sludge tumefaciens arc Ness (Propionibacterium acnes ) are present in the skin. These fungi decompose the sebum and sweat secreted on the skin to generate an odor. In addition, the degradation products stimulate the skin and cause inflammation. Propionibacterium acnes , in particular, uses lipase, a fatty acid degrading enzyme, to decompose sebum to produce free fatty acids. These free fatty acids not only stimulate the skin but also cause inflammatory lesions such as papules, pustules, and nodules, which are red rashes found in acne.

Antimicrobial compounds such as triclocarban and triclosan have been used as antimicrobial agents against such bacteria, but they are known to cause side effects such as skin burning, burning, and skin redness during long-term use.

Therefore, the development of new medicines having anti-inflammation, antimicrobial activity and the like with low side effects is still required.

The present invention discloses an extract of Porphyra japonica having anti-inflammatory and antibacterial activity.

It is an object of the present invention to provide a composition for anti-inflammation using pure extract of essential oil.

Another object of the present invention is to provide a composition for antimicrobial use using a pure extract of essential oil.

Other objects and specific objects of the present invention will be described below.

As shown in the following Examples and Experimental Examples, the present invention provides a method for inhibiting NO production and inhibiting the production of inflammatory cytokines in a murine macrophage cell line stimulated by LPS, ( Propionibacterium acnes CCARM 9009), Staphylococcus epidermidis CCARM 3709 ( Staphylococcus epidermidis CCARM 3709), Staphylococcus epidermidis , and Staphylococcus aureus CCARM 0027 (Staphylococcus aureus) Staphylococcus aureus CCARM 0027).

In one aspect, the present invention relates to an anti-inflammatory composition comprising an essential oil extract of Porphyra leaf or fruit as an active ingredient. In another aspect, the present invention relates to an anti-inflammatory composition comprising an essential oil extract of Pseudomonas sp. The present invention relates to an antimicrobial composition comprising, as an active ingredient, propionibacterium acnes, Staphylococcus epidermis, or Strontococcus aureus.

Since the antimicrobial composition of the present invention shows a high antimicrobial activity against Propionibacterium acnes, it can be suitably used for improving acne (i.e., treating, preventing or alleviating symptoms) caused by Propionibacterium acnes have.

In the present specification, the term "extract of pure alfalfa or fruit essential oil" refers to an extract of an oil phase obtained by condensing a perfume component from a leaf or fruit of pure alfalfa to be extracted. The preparation of the essential oil extract includes steam distillation, a solvent extraction method using a volatile solvent (benzene, ether, hexane, etc.) or a nonvolatile solvent (such as copper or vegetable oil), a leaching method , Supercritical extraction method, and the like can be used. Preferably, the extract is obtained by a solvent extraction method as specifically confirmed in the following examples, and specifically refers to an extract obtained by using hexane as a solvent, or a liquid or solid form obtained by extracting the obtained product with ethanol or a mixed solvent of ethanol and water .

In the present specification, the term " active ingredient " alone means an ingredient which exhibits the desired activity or which can exhibit activity together with a carrier which is not itself active.

As used herein, " anti-inflammatory " is meant to include improvement of an inflammatory disease (alleviation of symptoms), treatment, inhibition or delay of onset of such a disease as defined below.

In the present specification, the term " inflammatory disease " means an inflammatory reaction that is determined by an external physical or chemical stimulus or an infection of an external infectious source such as bacteria, fungi, viruses, various allergenic substances, or a local or systemic defense against autoimmunity Which may be defined as a pathological symptom. These inflammatory responses are caused by activation of various inflammatory mediators and enzymes associated with immune cells (e.g., iNOS, COX-2, etc.), secretion of inflammatory mediators (e.g., secretion of NO, TNF-a, IL-6, Cell migration, and tissue destruction, and manifest externally by symptoms such as erythema, pain, edema, fever, loss or loss of specific function of the body. The inflammatory disease may be acute, chronic, ulcerative, allergic or necrotic, so long as it is included in the definition of inflammatory diseases as above, it may be acute, chronic, ulcerative, allergic, Whether it is necrotic or not. Specifically, the inflammatory diseases include asthma, allergic and non-allergic rhinitis, chronic and acute rhinitis, chronic and acute gastritis or enteritis, ulcerative gastritis, acute and chronic nephritis, acute and chronic hepatitis, chronic obstructive pulmonary disease, Inflammatory bowel syndrome, inflammatory pain, migraine headache, headache, back pain, fibromyalgia, fascia disease, viral infection (e.g., C type infection), bacterial infection, fungal infection, burn, wound due to surgical or dental surgery, Rheumatoid arthritis, ankylosing spondylitis, Hodgkin's disease, pancreatitis, conjunctivitis, iritis, scleritis, uveitis, dermatitis (including atopic dermatitis), eczema, multiple sclerosis, etc. Will be included.

The anti-inflammatory composition of the present invention and the composition for antibacterial activity (hereinafter referred to as " anti-inflammatory composition or the like " of the present invention) can be used for improving the activity, antibacterial activity, and the like of an inflammatory disease intended to be treated depending on the use, formulation, (Effective amount) as long as it can be indicated, and a typical effective amount will be determined within the range of 0.001 wt% to 15 wt% based on the total weight of the composition. The term " effective amount " as used herein refers to an amount of an effective amount of a compound of the present invention to be administered to a mammal, preferably a human, to which the composition of the present invention is administered during a period of administration, / Delay, etc., of the active ingredient, which may be indicative of a medical or pharmacological effect. Such effective amounts can be determined experimentally within the ordinary skill of those skilled in the art.

The composition for anti-inflammation of the present invention may further contain, in addition to the active ingredient, any compound or natural extract known to have safety and anti-inflammatory activity for the purpose of raising or reinforcing the anti-inflammatory effect . Specific examples of such compounds or extracts include MSM (dimethylsulfonylmethane), N-acetylglucosamine, glucosamine, and individual approval under the Health Functional Foods Act Complex extracts of CMO-containing complex extracts such as FAT (Fatty acid Complex) and Gassiogarifolia, complex extracts such as turmeric extract, chicken breast cartilage powder, rosehip powder, boswellia extract, beeswax alcohol, , Green lipped mussel extract oil, hop extract, and gold extract. Such compounds or natural extracts may be included in the anti-inflammatory compositions of the present invention in combination with one or more of their effectiveness.

The anti-inflammatory composition and the like of the present invention can be grasped as a food composition in a specific aspect.

The food composition of the present invention can be produced in any form and can be used in various forms such as beverages such as tea, juice, carbonated drink, ionic drink, processed oil such as milk and yogurt, gum, rice cake, Korean confectionery, A food, a health food, a food, a tablet, a capsule, a ring, a granule, a liquid, a powder, a slice, a paste, a syrup, a gel, a jelly and a bar. In addition, the food composition of the present invention may be classified into any product category as long as it meets the laws and regulations on the time of manufacture and distribution in the legal and functional category. For example, it may be a health functional food according to the Act on Health Functional Foods, or a confectionery, bean curd, fermented beverages, special-purpose foods, etc. according to each type of food in the food revolution (food standard, .

The food composition of the present invention may contain food additives in addition to the active ingredients thereof. Food additives are generally understood to be substances that are added to foods and mixed or infiltrated into food in the manufacture, processing or preservation of food, and their safety must be ensured since they are taken daily with food and for long periods. Food additives according to the Food Hygiene Act (food additives notification, food additive standards and standards) are limited by the classification of safe synthetic food additives as chemical synthetic products, natural additives and mixed preparations.

These functional food additives can be classified into sweeteners, flavors, preservatives, emulsifiers, acidifiers, and thickeners.

A sweetener is used to impart a sweet taste suitable for foods, and natural or synthetic sweeteners can be used. Preferably, natural sweeteners are used. Examples of natural sweeteners include sugar sweeteners such as corn syrup solids, honey, sucrose, fructose, lactose and maltose.

Flavors may be used to enhance taste or flavor, both natural and synthetic. Preferably, a natural one is used. When using natural ones, the purpose of nutritional fortification can be performed in addition to the flavor. Examples of natural flavoring agents include those obtained from apples, lemons, citrus fruits, grapes, strawberries, peaches, and the like, or those obtained from green tea leaves, Asiatica, Daegu, Cinnamon, Chrysanthemum leaves and Jasmine. Also, those obtained from ginseng (red ginseng), bamboo shoots, aloe vera, banks and the like can be used. The natural flavoring agent may be a liquid concentrate or a solid form of extract. Synthetic flavors may be used depending on the case, and synthetic flavors such as esters, alcohols, aldehydes, terpenes and the like may be used.

As the preservative, calcium sorbate, sodium sorbate, potassium sorbate, calcium benzoate, sodium benzoate, potassium benzoate and EDTA (ethylenediaminetetraacetic acid) can be used. As the emulsifier, acacia gum, carboxymethyl cellulose, Pectin and the like. As the acidulant, math, malic acid, fumaric acid, adipic acid, phosphoric acid, gluconic acid, tartaric acid, ascorbic acid, acetic acid, phosphoric acid and the like can be used. The acidulant may be added so that the food composition has a proper acidity for the purpose of inhibiting the growth of microorganisms other than the purpose of enhancing the taste.

Examples of the thickening agent include suspending agents, sedimentation agents, gel-forming agents, bulking agents and the like.

The food composition of the present invention may contain physiologically active substances or minerals which are known in the art and which are stable as a food additive in addition to the above-mentioned food additives in order to supplement and supplement functional and nutritional properties.

Examples of such physiologically active substances include catechins contained in green tea and the like, vitamins such as vitamin B1, vitamin C, vitamin E and vitamin B12, tocopherol, dibenzoyl thiamine, etc. Examples of minerals include calcium preparations such as calcium citrate, magnesium stearate , Iron preparations such as iron citrate, chromium chloride, potassium iodide, selenium, germanium, vanadium, zinc and the like.

The food composition of the present invention may contain an appropriate amount of the above-mentioned food additives according to the product type so as to achieve the purpose of addition thereof.

With regard to other food additives that can be included in the food composition of the present invention, reference may be made to the Food Code or the Food Additive Code.

The composition for anti-inflammation of the present invention and the like may be regarded as a pharmaceutical composition in another specific embodiment.

The pharmaceutical composition of the present invention may be prepared into oral formulations or parenteral formulations according to the route of administration by conventional methods known in the art, including pharmaceutically acceptable carriers in addition to the active ingredient. The term " pharmaceutically acceptable " as used herein means that the application (prescribing) subject does not have the above-mentioned toxicity that is adaptable without inhibiting the activity of the active ingredient.

When the pharmaceutical composition of the present invention is prepared into an oral formulation, it may be formulated into powder, granules, tablets, pills, sugar tablets, capsules, solutions, gels, syrups, suspensions, wafers And the like. Examples of suitable pharmaceutically acceptable carriers include sugars such as lactose, glucose, sucrose, dextrose, sorbitol, mannitol, xylitol, starch such as corn starch, potato starch and wheat starch, cellulose, methylcellulose, ethylcellulose, Cellulose derivatives such as sodium carboxymethyl cellulose and hydroxypropylmethyl cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, magnesium stearate, mineral oil, malt, gelatin, talc, And the like. In case of formulation, a diluent such as a filler, an extender, a binder, a wetting agent, a disintegrant, a surfactant, and / or an excipient may be formulated according to need.

When the pharmaceutical composition of the present invention is prepared into a parenteral dosage form, it may be formulated in the form of an injection, transdermal drug delivery, nasal aspirate and suppository together with a suitable carrier according to methods known in the art. Examples of suitable carrier in the case of formulation with an injectable preparation include sterilized water, ethanol, polyol such as glycerol and propylene glycol, or a mixture thereof. Preferably, the carrier is selected from the group consisting of Ringer's solution, phosphate buffered saline containing triethanolamine, Water, or isotonic solution such as 5% dextrose may be used. When formulated with a transdermal drug, it can be formulated in the form of an ointment, a cream, a lotion, a gel, a solution for external use, a pasta, a liniment, or an air-roll. The nasal inhalant may be formulated in the form of an aerosol spray using a suitable propellant such as dichlorofluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide, etc. When formulated as a suppository, witepsol, tween 61, polyethylene glycols, cacao butter, laurin, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene stearates, and sorbitan fatty acid esters.

The formulation of pharmaceutical compositions is well known in the art and can be specifically described in Remington ' s Pharmaceutical Sciences (19th ed., 1995). This document is considered part of this specification.

The preferred dosage of the pharmaceutical composition of the present invention is 0.001 mg / kg to 10 g / kg per day, preferably 0.001 mg / kg to 1 g / day, depending on the patient's condition, body weight, sex, age, / kg < / RTI > The administration can be carried out once or several times a day. Such dosages should in no way be construed as limiting the scope of the invention.

In another specific embodiment, the composition for anti-inflammation of the present invention can be identified as a cosmetic composition. When the anti-inflammatory composition of the present invention is identified as a cosmetic composition, its use can be understood as a relief of inflammatory skin irritation.

The cosmetic composition of the present invention may contain, in addition to its active ingredient, conventional additives such as stabilizers, solubilizing agents, surfactants, vitamins, colorants and antioxidants, and carriers commonly used in cosmetic compositions.

The cosmetic composition of the present invention can be prepared into any of the formulations conventionally produced in the art and can be used in the form of solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, , Oil, powder foundation, emulsion foundation, wax foundation and spray, but is not limited thereto. More specifically, it can be manufactured in the form of a soft lotion, a nutritional lotion, a nutritional cream, a massage cream, an essence, an eye cream, a cleansing cream, a cleansing foam, a cleansing water, a pack, a spray or a powder.

When the formulation of the present invention is a paste, cream or gel, an animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as the carrier component .

When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In the case of a spray, in particular, / Propane or dimethyl ether.

When the formulation of the present invention is a solution or an emulsion, a solvent, a dissolving agent or an emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, , 3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan fatty acid esters.

In the case where the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. may be used.

When the formulation of the present invention is an interfacial active agent-containing cleansing, the carrier component is selected from aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters.

The cosmetic composition of the present invention can be manufactured according to a method for producing a cosmetic composition which is conventionally performed in the art, except that it contains the active ingredient exhibiting anti-inflammatory activity and the like.

As described above, the present invention can provide an anti-inflammatory or antimicrobial composition using the extract of Porphyra japonica essential oil. The composition of the present invention can be commercialized as food, medicine or cosmetics.

Fig. 1 shows the results of experiments showing the NO production inhibitory activity of the extracts of Pseudomonas sp.
FIG. 2 shows the results of experiments showing the inhibitory activity of inflammatory cytokine production of the extract of Pseudomonas sp.

Hereinafter, the present invention will be described with reference to Examples and Experimental Examples. However, the scope of the present invention is not limited to these examples and experimental examples.

<Examples> Preparation of Extracts of Sunflower Seed Oil

202.7 g of the lyophilized pure alfalfa leaves and 399.3 g of the fruit were each stirred in 2 L of hexane for 3 hours, filtered and concentrated using a vacuum concentrator. The solvent was volatilized and the residual cone ceded was recovered and mixed with 500 mL of distilled water (95% ethanol) to separate the essential oil soluble in the extraction solvent and remove the solvent.

<Experimental Example> Anti-inflammatory activity and antibacterial activity test

<Experimental Example 1> Anti-inflammatory activity test

(1) Cell culture

RAW264.7, a murine macrophage cell line used in inflammatory activity experiments, was purchased from Korean Cell Line Bank (KCLB). The cells were cultured in DMEM medium (Dulbecco's modified Eagle's minimal essential medium) containing 1% antibiotic (Gibco, USA) and 10% fetal bovine serum (FBS) And subcultured once a day. LPS (Lipopolysaccharide) was purchased from Sigma-Aldrich (St. Louis, Mo., USA).

(2) Nitric oxide (NO) measurement

RAW264.7 cells were plated at 1.5 × 10 ⁵ cells / well in a 24-well plate and cultured for 18 hours. Then, the sample was incubated with 1 μg / ml of LPS at the same time for 24 hours. The amount of nitrogen monoxide produced was measured in terms of the NO ² form present in the cell culture medium using a griess reagent (Sigma). 100 μl of the cell culture supernatant and 100 μl of the griess reagent were mixed and reacted on a 96-well plate for 10 minutes, and the absorbance was measured at 540 nm. The results are shown in Fig. 1 as a percentage of the untreated group. As shown in Fig. 1, NO generation was suppressed in proportion to the treatment concentration.

(3) Inflammatory cytokine measurement

RAW264.7 cells were plated at a rate of 1.5 × 10 ⁵ cells / well in a 24-well plate, cultured for 24 hours, treated with 1 μg / ml of LPS to stimulate the production of inflammatory cytokines, and treated at the same time. After culturing for 24 hours, centrifugation (12,000 rpm, 3 min) was performed to measure the inflammatory cytokine of the supernatant obtained by ELISA kit (R & D systems, USA). The results are shown in Fig. 2 as a percentage of the untreated group. As can be seen in FIG. 2, the essential oil extract of Pseudomonas externa did not exhibit the activity of inhibiting the production of inflammatory cytokines, but the extract of the essential oils showed a high inhibitory activity in proportion to the treatment concentration.

&Lt; Experimental Example 2 >

(1) Culture of the strain

A strain of Staphylococcus epidermidis CCARM 3709, which is an acne bacterium, Propionibacterium acnes CCARM 9009, Staphylococcus epidermidis CCARM 3709, Staphylococcus epidermidis CCARM 3709, and Staphylococcus aureus CCARM Staphylococcus aureus CCARM 0027 was purchased from CCARM (Culture Collection of Antimicrobial Resistant Microbes).

The LB agar medium, tryptic soy agar medium and gifu anaerobic medium were purchased from Difco La (Sparks, MD, USA) as a medium for culturing the strain. Respectively. Staphylococcus epidermis and Stilylococcus aureus were cultured under aerobic condition at 37 ° C and subcultured every 24 hours. Propionibacterium acnes were incubated at 37 ℃ anaerobic condition and cultured for 24 ~ 48 hours.

(2) Measurement of minimum inhibitory concentration (MIC)

The minimum inhibitory concentration (MIC) is the minimum concentration of antibiotic that inhibits the growth of microorganisms. The lower the MIC value for the microorganism, the higher the susceptibility of the sample material to the microorganism. MIC measurements were made using a modified broth dilution method. After adding 100 μl of the medium containing the sample to the 96-well plate, the concentration of the suspension was adjusted to 2 × 10 ⁵ CFU / ml, and 100 μl of the suspension was added. Staphylococcus epidermis and stilylococcus aureus were cultured at 37 ° C for 24 hours. Propionibacterium acnes were incubated at 37 ° C under anaerobic conditions for 48 hours. Thereafter, the minimum concentration at which no bacterial growth was observed was confirmed, and the results are shown in Table 1 below. As shown in Table 1 below, the essential oil extract of Pseudomonas sp. Leaves showed higher antimicrobial activity against all three strains than the essential oil extract. Especially, it showed high antimicrobial activity against Propionibacterium acnes.

Strain Antibiotic susceptibility (MIC, / / ml) MIC (㎍ / ml) of leaf essential oil extract MBC (㎍ / ml) of leaf essential oil extract MIC (㎍ / ml) of fruit essential oil extract MBC (㎍ / ml) of fruit essential oil extract P. acnes
CCARM 9009 Clindamycin
(64) 62.5 250 62.5 1000 S. epidermis
CCARM 3709 Susceptible 250 500 2000 > 2000 S. aureus
CCARM 0027 - 500 2000 2000 > 2000

(3) Measurement of MBC (minimum bactericidal concentration)

The lower MIC value does not mean that all of the microorganisms are killed at that concentration. Since the microorganism does not grow due to the influence of the sample, the minimum bactericidal concentration (MBC) Sample cultures at higher concentrations than those indicated were treated with hard medium (1.5% agar) to confirm formation of colonies. The sample medium in which the MIC was subjected to 1.5% agar medium was streaked and cultured. Cocosporidemis and Stratylococus aureus were cultured at 37 ° C. for 24 hours. Propionibacterium acnes were incubated at 37 ° C. under anaerobic conditions for 48 hours to determine the minimum concentration at which no colonies were formed . The results are shown together in Table 1 above. Similar to the MIC results, the essential oil extract of Panax notoginsophila showed higher antimicrobial activity against all three strains than the essential oil extract, and showed particularly high antimicrobial activity against Propionibacterium acnes.

Claims (7)

delete An antimicrobial composition for Propionibacterium acnes containing an extract of Pseudomonas sp. Or an essential oil extract as an active ingredient.
3. The method of claim 2,
Wherein the essential oil extract is obtained by extracting Porphyra wood with hexane and then extracting the hexane extract with a mixed solvent of water and ethanol.
The method according to claim 2 or 3,
Wherein the composition is a food composition.
The method according to claim 2 or 3,
Wherein the composition is a cosmetic composition.
The method according to claim 2 or 3,
Wherein the composition is a pharmaceutical composition.
The method according to claim 6,
Wherein the composition has a pharmacological effect of treating or preventing acne.

Images